Thors have study and agreed to the published version with the manuscript. Funding: This work was supported in portion by the European Project THINPAD “Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance” (FP7-Grant Agreement 601969), by Foundation Clinic, by ANRS, by SIDACTION, and with federal funds from the NCI/NIH, below Contract No. HHSN261200800001E with Leidos Biomedical Analysis, Inc. The content of this publication doesn’t necessarily reflect the views or policies from the Division of Wellness and Human Services, nor does mention of trade names, industrial solutions, or organizations imply endorsement by the U.S. Government (R.J.G.). S.L. acknowledges funding by the Marie-Curie IEF fellowship (FP7Grant Agreement 237738) and is grateful to Maria Sol(IBMB-CSIC). S.K.S. and a.M. acknowledge help from amfAR Mathilde Krim Fellowship in Basic Biomedical Analysis quantity 108680 plus the Spanish Ministry of Economy and Competitiveness and FEDER (Grant no. SAF2013-46077-R). S.K.S. also gratefully acknowledges help from the Volkswagen Foundation “Experiment! Funding Initiative” grant quantity 93874 and from the Klaus Tschira Stiftung. Institutional Critique Board Statement: Not applicable. Informed Consent Statement: Not applicable. Acknowledgments: We thank Carlo Carolis, Biomolecular Screening and Protein Technology Unit (CRG); Carmen Lopez Iglesias along with the TEM-SEM facilities of Science and Technical Centers of your Universitat de Barcelona (CCiT-UB); Cathy V. Hixson and Donald G. Johnson of Leidos Biomedical Research, Inc.; Chahrazade El Amri (Sorbonne Universit); Delphine Muriaux (IRIM, CNRS); and Eric Le Cam (IGR and CNRS). The authors dedicate this function to the memory of Louis E. Henderson.Viruses 2021, 13,21 ofConflicts of Interest: The authors declare no conflict of interest.AbbreviationsThe following abbreviations are applied within this manuscript: HIV RNA Human immunodeficiency virus Ribonucleic acid
virusesArticleExploring the Diversity with the Human Blood ViromeMar CebriMendoza 1 , Mar A. Bracho two,three , Cristina Arbona 4 , Lu Larrea 4 , Wladimiro D z 1,5 , Rafael Sanju 1,6 and JosM. Cuevas 1,six, 35Institute for Integrative Systems Biology (I2SysBio), Universitat de Val cia-CSIC, 46980 Val cia, Spain; [email protected] (M.C.-M.); [email protected] (W.D.); [email protected] (R.S.) Joint Study Unit “Infection and Public Health”, FISABIO-Universitat de Val cia I2SysBio, 46020 Val cia, Spain; [email protected] CIBER in Epidemiology and Public Wellness (Alvelestat Inhibitor CIBERESP), 46020 Val cia, Spain Centro de Transfusi de la Comunidad Valenciana, 46020 Val cia, Spain; [email protected] (C.A.); [email protected] (L.L.) Division of Informatics, Universitat de Val cia, 46020 Val cia, Spain Division of Genetics, Universitat de Val cia, 46020 Val cia, Spain Correspondence: [email protected]: CebriMendoza, M.; Bracho, M.A.; Arbona, C.; Larrea, L.; D z, W.; Sanju , R.; Cuevas, J.M. Exploring the Diversity on the Human Blood Virome. Viruses 2021, 13, 2322. https://doi.org/10.3390/v13112322 Academic Editors: Franziska Hufsky, Alba P ez-Catalu , Walter Randazzo, Gloria Sanchez, Fernando Gonz ez-Candelas and Manja MarzAbstract: Metagenomics is greatly enhancing our ability to find out new viruses, at the same time as their attainable associations with illness. On the other hand, metagenomics has also changed our understanding of viruses generally. The vast expansion of at the moment known viral diversity has (Z)-Semaxanib MedChemExpress revealed a big fraction of non-pathogenic.
